Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 359

1.

[Morphological signs of inflammatory activity in different clinical forms of drug-resistant pulmonary tuberculosis].

Elipashev AA, Nikolsky VO, Shprykov AS.

Arkh Patol. 2017;79(4):13-17. doi: 10.17116/patol201779413-17. Russian.

PMID:
28791993
2.

A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.

Ahmed M, Smith DM, Hamouda T, Rangel-Moreno J, Fattom A, Khader SA.

Vaccine. 2017 Jul 31. pii: S0264-410X(17)30981-7. doi: 10.1016/j.vaccine.2017.07.073. [Epub ahead of print]

PMID:
28774560
3.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct 15;23(10). doi: 10.3201/eid2310.170834. [Epub ahead of print]

4.

Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.

Prasad R, Singh A, Balasubramanian V, Gupta N.

Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16. Review.

5.

First Insight into a Nationwide Genotypic Diversity of <i>Mycobacterium tuberculosis</i> among Previously Treated Pulmonary Tuberculosis Cases in Benin, West Africa.

Affolabi D, Sanoussi N, Codo S, Sogbo F, Wachinou P, Massou F, Kehinde A, Anagonou S.

Can J Infect Dis Med Microbiol. 2017;2017:3276240. doi: 10.1155/2017/3276240. Epub 2017 Jun 21.

6.

Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014.

Tasbiti AH, Yari S, Ghanei M, Shokrgozar MA, Fateh A, Bahrmand A.

Osong Public Health Res Perspect. 2017 Apr;8(2):116-123. doi: 10.24171/j.phrp.2017.8.2.03. Epub 2017 Apr 30.

7.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

PMID:
28529205
8.

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.

PMID:
28507117
9.

First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> in Saudi Arabia.

Varghese B, Al-Hajoj S.

Am J Trop Med Hyg. 2017 May;96(5):1066-1070. doi: 10.4269/ajtmh.16-0579.

PMID:
28500800
10.

Recent developments of coumarin-containing derivatives and their anti-tubercular activity.

Hu YQ, Xu Z, Zhang S, Wu X, Ding JW, Lv ZS, Feng LS.

Eur J Med Chem. 2017 Aug 18;136:122-130. doi: 10.1016/j.ejmech.2017.05.004. Epub 2017 May 2.

PMID:
28494250
11.

Clinical outcomes for multi- and extensively drug resistant tuberculosis patients with adjunctive resectional lung surgery in Beijing, China.

Ma Y, Pang Y, Du J, Liu Y, Li L, Gao W.

J Thorac Dis. 2017 Mar;9(3):841-845. doi: 10.21037/jtd.2017.02.54.

12.

Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.

Chen J, Peng P, Du Y, Ren Y, Chen L, Rao Y, Wang W.

BMC Infect Dis. 2017 Apr 24;17(1):300. doi: 10.1186/s12879-017-2409-6.

13.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
14.

An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.

Bastos ML, Lan Z, Menzies D.

Eur Respir J. 2017 Mar 22;49(3). pii: 1600803. doi: 10.1183/13993003.00803-2016. Print 2017 Mar.

PMID:
28331031
16.

Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012-2014.

Lemus D, Echemendía M, Díaz R, Llanes MJ, Suárez L, Marrero A.

MEDICC Rev. 2017 Jan;19(1):10-15.

17.

Patterns of drug resistance among patients with tuberculous pleural effusion in Greece.

Anastasakos V, Skouras V, Moschos C, Tsikrika S, Karabela S, Marinou I, Vogiatzakis E, Konstantinou K, Papavasiliou A, Kalomenidis I.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):309-313. doi: 10.5588/ijtld.16.0155.

PMID:
28225341
18.

Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.

Javaid A, Hasan R, Zafar A, Chaudry MA, Qayyum S, Qadeer E, Shaheen Z, Agha N, Rizvi N, Afridi MZ, Chima MK, Khan AR, Ghafoor A, Khan S, Awan SR, Akhtar S, Choudry K, Iqbal ZH, Ansarie M, Ahmad N.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):303-308. doi: 10.5588/ijtld.16.0444.

PMID:
28225340
19.

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.

Lee JY, Kim DK, Lee JK, Yoon HI, Jeong I, Heo E, Park YS, Lee JH, Park SS, Lee SM, Lee CH, Lee J, Choi SM, Park JS, Joh JS, Cho YJ, Lee YJ, Kim SJ, Hwang YR, Kim H, Ki J, Choi H, Han J, Ahn H, Hahn S, Yim JJ.

Trials. 2017 Feb 13;18(1):68. doi: 10.1186/s13063-017-1811-0.

20.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

Supplemental Content

Loading ...
Support Center